Ken Warrington
Director/Board Member at BIOSTEM TECHNOLOGIES INC
Profile
Ken Warrington is currently the Director at BioStem Technologies, Inc. He previously worked as the Chief Technology Officer at Lacerta Therapeutics, Inc. from 2017 to 2019.
In 2020 to 2021, he was the Head-Strategy & Innovations at GENSCRIPT PROBIO USA INC.
Prior to that, from 2019 to 2020, he served as the Senior VP-Operations & Business Development at Biostem Life Sciences, Inc. Mr. Warrington holds a doctorate degree from the University of Florida, which he obtained in 2000.
He also has an undergraduate degree from The St. Lawrence College, which he received in 1993.
Ken Warrington active positions
| Companies | Position | Start |
|---|---|---|
| BIOSTEM TECHNOLOGIES INC | Director/Board Member | 28/02/2022 |
Former positions of Ken Warrington
| Companies | Position | End |
|---|---|---|
| GENSCRIPT PROBIO USA INC. | Corporate Officer/Principal | 30/11/2021 |
| Biostem Life Sciences, Inc. | Chief Operating Officer | 30/04/2020 |
Lacerta Therapeutics, Inc.
 Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Chief Tech/Sci/R&D Officer | 30/04/2019 |
Training of Ken Warrington
| University of Florida | Doctorate Degree |
| The St. Lawrence College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOSTEM TECHNOLOGIES INC | Health Technology |
| Private companies | 3 |
|---|---|
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Health Technology |
| GENSCRIPT PROBIO USA INC. | |
| Biostem Life Sciences, Inc. |
- Stock Market
- Insiders
- Ken Warrington
